GLIDE Teaming Profiles
Thank you for showing an interest in ARPA-H’s Groundbreaking Lymphatic Interventions and Drug Exploration (GLIDE) program. This page is designed to help facilitate connections between prospective proposers. If either you or your organization are interested in teaming, please submit your information via the portal linked below. Your details will then be added to the list below, which is publicly available.
GLIDE anticipates that teaming will be necessary to achieve the goals of the program. Prospective performers are highly encouraged (but not required) to form teams with varied technical expertise to submit a proposal to the GLIDE solicitation.
Please note that by publishing the teaming profiles list, ARPA-H is not endorsing, sponsoring, or otherwise evaluating the qualifications of the individuals or organizations included here. Submissions to the teaming profiles list are reviewed and updated periodically.
Interested in learning more about the GLIDE program?
- Read the GLIDE solicitation.
- GLIDE program overview page.
Teaming Profiles List
To narrow the results in the Teaming Profiles List, please use the input below to filter results based on your search term. The list will filter as you type.
| Contact | Organization Name | Location | Description of Research Focus Area | Description of Teaming Partner | Technical Areas | |
| Gary Binyamin | Zero Slop Labs | gbinyamin@gmail.com | Berkeley, CA | We are committed to enabling minimally-invasive, lymphatic interventions. Lymphatics are integral to most major human systems, contributing to both immune and circulatory effects. The company’s first program is focused on the restoration of lymphatic homeostasis, with follow-on programs in lymphatic immunomodulation and lymphatic diagnostic evaluation & monitoring | Academic partners, patients, clinicians, other organizations to support development, therapeutic molecules (small & large) for delivery | TA1: Restore Flow Through Physical Interventions, TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Renata Pasqualini | Rutgers Biomedical and Health Sciences | renata.pasqualini@rutgers.edu | Newark, NJ | Ligand-directed delivery to lymphatic vessels based on in vivo phage display | Therapeutic payloads to restore lymphatic function, particularly in complications associated to breast cancer | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Nathan Schilaty | University of South Florida | nschilaty@usf.edu | Tampa, FL | Cervical force-based manipulation for improving glymphatic neurovascular flow | Advanced imaging analysis of glymphatic flow and neck vascularity | TA1: Restore Flow Through Physical Interventions |
| Tom Hu | University of Colorado | tom.cc.hu@gmail.com | Aurora, CO | Molecular Imaging | Therapeutics and Diagnostics companies | TA1: Restore Flow Through Physical Interventions |
| Don Tucker | Brain Electrophysiology Laboratory Company | don.tucker@bel.company | Eugene, OR | We provide transcranial electrical stimulation to synchronize the slow oscillations of deep sleep, thereby improving glymphatic clearance of metabolic toxins from the brain. | Collaborators with unique glymphatic function assessment capabilities. | TA1: Restore Flow Through Physical Interventions |
| Stephanie Legere | CCRM | stephanie.legere@ccrm.ca | Toronto, Ontario, Canada | CCRM is a non-profit organization supporting the development & commercialization of cell & gene therapy (CGT) approaches for regenerative medicine. We have a broad network in this space & a strong history of developing CGT technologies, as well as manufacturing capabilities for Phase I/II clinical trials. We are currently interested in understanding how CGT-based modification of the glymphatic system could be used therapeutically for various neurodegenerative diseases or brain injuries. | CCRM collaborates with industry and academic partners around the world to develop new therapies and technologies that can be spun out into companies. We are looking for academic partners that have lab-based capabilities for exploring glymphatic function. We are particularly interested in those with established animal models and methods for assessing glymphatic function in the context of brain injury or neurodegenerative disease. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Carolyn De La Cruz | UPMC | delacx@upmc.edu | Pittsburgh, PA | Our clinical team has expertise in diagnostics and treatment for lymphedema patients. In addition, our translational science team uses a well-established small animal model with large animal capabilities to understand the role of lymphatics on nerve healing. Specifically, we have expertise with icg imaging, ultrasound and clinical assessment and treatment of lymphedema using conservative and surgical techniques. We focus on lymphatic dysfunction in breast cancer patients and general populations. | Our team is looking for partners in drug delivery platforms and imaging to study lymphatic function. We have shown the clincal development of new lymphatic pathways and altered lymphatic function in patients. We seek others to partner in pre-clinical and clinical trials and the ability to understand these findings and advance the science. | TA1: Restore Flow Through Physical Interventions |
| sheila ridner | Vanderbilt University | sheila.ridner@vanderbilt.edu | Nashville, TN | Areas include: physical interventions (devices and garments) for lymphedema treatment and prevention and physiological and patient reported outcome measures. | Innovative thinkers with patient access. Willingness to challenge current treatment and measurement approaches. | TA1: Restore Flow Through Physical Interventions |
| Noo Li Jeon | SNU | nljeon@gmail.com | Republic of Korea | perfusable vessels on a chip, MPS | bio expertise | TA1: Restore Flow Through Physical Interventions |
| Sanjeev Datar | UCSF | sanjeev.datar@ucsf.edu | San Francisco, CA | We study pulmonary lymphatics in the context of a large animal model of congenital heart disease. Our studies focus on how a flow-reponsive mechanosensory signaling cascade leads to HIF-1a stabilization and endothelial injury. We have shown the benefit of a promising pharmacoloagic therapy that preserves lymphatic endothelial function in this setting, in vivo. This would be the focus of our TA2 application, and we would love pre-clinical and clinical trial partners. | pre-clinical and clinical trial partners | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Dino Ravnic | Penn State University | dur2@psu.edu | Hershey, PA | We have recently developed a novel microsurgical approach, termed micropuncture, that can rapidly stimulate angiogenesis. Combining micropuncture with a variety of biomaterials has allowed us to precisely control capillary growth and development. We hypothesize that our novel microsurgical approach can also be used to trigger lymphangiogenesis. | We are looking for academic collaborators with established animal models of lymphedema and lymphatic dysfunction to test the effectiveness (and mechanisms) of our novel microsurgical approach in the context of lymphedema, with the end-goal being human trials. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Rashad Hussain | University of Rochester, NY | rashad_hussain@urmc.rochester.edu | Rochester, NY | We develop innovative imaging modalities and refined a pharmacological approach to mitigate injury-induced edema. Utilizing high-speed, high-resolution two-photon imaging, we gained significant insights into the fluid flow dynamics of lymphatic vessels. Leveraging our advanced imaging techniques and AI-assisted analytical strategies, we gained key insights into lymphatic vessel contraction rhythms and fluid transfer, enabling us to propose novel solutions for lymphedema. | Our studies of pharmacological interventions in mitigating the edema are focused at preclinical models. Briefly, we see promising effect of pan-noradrenergic inhibitors, Bay K8644 and Glibenclamide in mitigating the lymphatic vessel dysfunction. We desire to find the partners in clinics and further advance our understanding of these interventions. | TA1: Restore Flow Through Physical Interventions |
| Aaron Rogers | Redwire | aaron.rogers@redwirespace.com | Greenville, IN | Improving Human Health Outcomes by Leveraging Microgravity | Ground based researchers with breakthroughs that could benefit from microgravity | TA1: Restore Flow Through Physical Interventions |
| Abhishek Jain | Texas A&M University | a.jain@tamu.edu | Houston, TX | Our lab contributes new organ-on-chip designs, particularly that include modeling single vessels (blood and lymphatic), vascular networks, hemo- and lympho-dynamics, and integration of these systems into complex tumor and pancreatic microenvironments. We have created a multicellular human lymphangion-chip and a lymphangiogenesis-chip that serves as a disease and drug discovery model to enable preclinical and translational research in lymphedema and rare lymphatic malformations, | We are looking for therapeutic development and clinical trial teams. We are also looking for entrepreneurs who can help with technology translation. | TA1: Restore Flow Through Physical Interventions |
| Kannappan Palaniappan | University of Missouri | palaniappank@missouri.edu | Columbia, MO | University of Missouri-Columbia basic science on the structure-function of lymphatics and blood vasculature in different tissues. | Strengthening therapeutic intervention studies in a clinical setting. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Valentina Triacca | Lymphatica Medtech SA | valentina.triacca@lymphatica.ch | EPFL Innovation Park, 1015 Lausanne - Switzerland | Lymphatica Medtech is a medical device development company based in Switzerland. Lymphatica is currently developing an minimally invasive implantable drainage device to bypass lymphatic blockage and recirculate lymphatic fluid. The device has been tested in a successful pilot feasibility trial in Switzerland, and we are currently preparing for the next phase of clinical investigations to complete device clinical validation. | We are looking for product development experts with strong background in market launch, reimbursement and commercialization of medical devices in the US. We would love to team up with a patient / parent ambassador based in the US and with a young investigator to complete the discovery duo program. Our expertise lies in R&D, manufacturing, quality and regulatory affairs and clinical study design. We are looking for team members to complement our skill sets. | TA1: Restore Flow Through Physical Interventions, TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Bob Wieden | Eva Medtec, Inc. | bwieden@evamedtec.com | Minneapolis, MN | We have developed a FDA cleared medical device, Neuroglide, that enhances lymphatic circulation and relieves pain. It automates the specialized Manual Lymphatic Drainage technique traditionally used by certified therapists addressing chronic conditions such as pain, lymphedema, arthritis, etc. and in post-op recovery therapy. | Looking for partners to explore new applications/conditions to treat and new therapeutic drug delivery methods that target the lymphatic system (or superficial fascial sensory network) and that could be used in conjunction with our device. | TA1: Restore Flow Through Physical Interventions, TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| John Cooke | Houston Methodist Research Institute | jpcooke@houstonmethodist.org | Houston, TX | We have formed a team which is focus on developing a product that involves robotic placement of proprietary collagen spheres linked to circular RNA, which encodes lymphangiogenic factors that leads to replication of lymphatic cells from the adjacent vessels, which then traffic towards the collagen to re-establish the vessels. | We have formed a base team but would be interested in partnering with both clinicians that treat lymphatic disorders as well as lymphatic biologists who would be interested in testing their biologics in our proposed product. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Berk Ozmen | Cleveland Clinic Foundation | ozmenb@ccf.org | Cleveland, OH | Surgical management of lymphedema, artificial intelligence applications in lymphedema microsurgery and supermicrosurgery, robotic surgery for lymphedema | Collaborations in AI and robotics for lymphedema surgery | TA2: Normalize Function Through Targeted Pharmacologic & Cell Therapy |
| Sameer Sonkusale | Tufts University | sameer@ece.tufts.edu | Medford, MA | Biomedical devices, Flexible Bioelectronics, Examples: Smart bandages, Microneedles, smart sutures, Sensors, Drug Delivery | Expertise in Lymphatic Disorders and treatments | TA2: Normalize Function Through Targeted Pharmacologic & Cell Therapy |
| John Powderly MD | Carolina BioOncology Institute, PLLC & BioCytics Inc | jpowderly@carolinabiooncology.org | Huntersville, NC | BioCytics Human Applications Lab is developing immune cell therapies derived from the lymphopoietic system, to fight cancer. Specifically, anti-cancer specific subfractions of exhausted-reinvigorated T-cells, gamma-delta T-cells, and naive T-cells educated by dendritic cells and autologous tumor antigens to recapitulate an ex-vivo lymph node. The exhausted-reinvigorated fractions is currently in pre-IND enabling R&D, optimization and beginning GMP upscaling. | Looking for teaming partners that may have synergistic technologies, such as public antigen vaccines, immune modulatory cytokines/agonists, gene editing constructs, and/or manufacturing technology platforms. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Valentina Triacca | Lymphatica Medtech SA | valentina.triacca@lymphatica.ch | Lausanne - Switzerland (US state indicated only to be able to submit the form), AL | Lymphatica Medtech is specialized in research and development of innovative implants for the treatment of lymphatic diseases. Lymphatica's team is interdisciplinary and combines mechanical, electrical, biomedical and software engineering skills with competence in quality, regulatory and clinical strategy. Lymphatica is ready to take on challenges related to the development of medical devices for the treatment of diseases related to body fluid management. | Lymphatica is looking for clinical teams willing to collaborate in the developement of devices by providing clinical inputs, and willing to participate in human factors, usability and clinical studies. | TA1: Restore Flow Through Physical Interventions |
| Summer Hanson | University of Chicago | Sehanson@bsd.uchicago.edu | Chicago, IL | The Section of Plastic and Reconstructive Surgery at the University of Chicago has experts in the field of supermicrosurgery and lymphatic reconstruction. We collaborate with our colleagues in molecular engineering and cellular and molecular biology as well as physical medicine and rehabilitation. | New collaborations across multiple institutions. | TA1: Restore Flow Through Physical Interventions |
| John Dougherty | Nobias Therapeutics | dougherty@nobiastx.com | Philadelphia, PA | Nobias is a clinical stage, pediatrics-focused rare disease biotechnology company. We have a program exploring MEK inhibitors for the treatment of complex lymphatic anomalies. | TBD | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Juan Rodolfo Mella | University of Miami | jrmella@med.miami.edu | Miami, FL | outcomes in lymphatic surgery. | share ideas, begin research collaborations, etc | TA1: Restore Flow Through Physical Interventions |
| Paulien Roos | CFD Research Corporation | paulien.roos@cfd-research.com | Huntsville, AL | Multiscale Quantitative Systems Pharmacology (computational), linking systemic and lymphatic components. Developing novel formulation and delivery of therapeutics targeting lymphatic dysfunction. | Preclinical and clinical studies of therapeutics targeting lymphatic dysfunction. Providing QSP tools for translational studies and for personalized treatment protocols | TA1: Restore Flow Through Physical Interventions |
| Mark Ereth | InSitu Biologics, Inc/Mayo Clinic | mark.ereth@insitubiologics.com | Woodbury/Rochester, MN | Mayo Clinic and InSitu Biologics have partnered in the development of drug delivery matrix via the lymphatic channels and lymph nodes. The team of clinicians, surgeons, scientists, and InSitu's team have developed and validated a novel delivery mechanism that can carry both large and small molecules. This delivery mechanism includes the ability to prolong elution rates, thereby delivering the active pharmaceutical ingredient to lymphatic structures for weeks instead of hours or days. | The ideal partner for the Mayo/InSitu Biologics team would have existing or novel anticancer or immune-modulating agent(s). They wish to deliver to lymphatic structures within our matrix that can be formulated, based upon the therapeutic needs, to elute over the course of a few days up to a few weeks. | TA1: Restore Flow Through Physical Interventions |
| Brian Ross | University of Michigan | bdross@med.umich.edu | Ann Arbor, MI | Our research team has expertise in small molecule drug development. Specifically, we have expertise with design and synthesis of orally dosed small molecule kinase inhibitors which are absorbed directly into the mesenteric lymphatics avoiding first-pass hepatic metabolism. | Our team is looking for in vitro lymphatic screening systems and importantly, established expertise in animal lymphatic disease models to work together on screening the potency of novel therapeutics to develop novel and efficacious interventions. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Irving Weinberg | Weinberg Medical Physics, Inc. | info@weinbergmedicalphysics.com | Rockville, MD | We are an incubator specializing in medical imaging and image-guided therapy. We have built an image-guided magnetic manipulation system that can guide magnetically catheters with about 30-micron resolution. We envision placing hair-thin catheters with multiple side apertures in tissue to replace damaged lymphatics. Our incubator has launched companies with aggregate values of hundreds of millions of dollars. | Sites for clinical and preclinical demonstrations. Catheter manufacturers. | TA1: Restore Flow Through Physical Interventions |
| Tina Bland | Grand Strand Clinical Trial Services, LLC | tinabland@gsclinical.com | Myrtle Beach, SC | Grand Strand Clinical Trial Services is a woman-owned small business that specialized in providing support services to teams preparing for or conducting pre-clinical research or clinical trials geared towards new drug or new device development. We provide a range of services including but not limited to consultative medical writing/essential document development, clinical operations team training and oversight, and outsourcing support. | We are seeking to subcontract under a prime provider to offer a range of services including but not limited to consultative medical writing/essential document development, clinical operations team training and oversight, and outsourcing support. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Dwight Lawrence | Mayo Clinic | lawrence.dwight@mayo.edu | Rochester, MN | Developing commercially viable regenerative biotherapeutics | - | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| David Brown | ImYoo | dbrown@imyoo.health | South San Francisco, CA | We are using at-home self-collection of blood to capture single-cell immune profiles of research participants to better understand autoimmune flares and drug mechanism. By capturing molecular signals on-demand at key moments in a disease trajectory, we believe we can identify more precise treatments for specific subpopulations of people. We are running studies on inflammatory bowel disease, rheumatoid arthritis, and psoriasis, but would love to work with people on additional indication areas. | We are looking for drug and diagnostic research groups (for-profit or non-profit) that have hypotheses in specific disease areas that could be elucidated with our approach. We want to work with people with disease expertise and combine our technology for at-home single-cell data and expertise in single-cell analysis and direct-to-patient study design to find new ways to target or resolve immune-mediated disorders. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Albert Kim | Massachusetts General Hospital | akim46@mgh.harvard.edu | Boston, MA | I lead a research group applying computer vision and deep learning analysis to medical images (histopathology, radiology) as a method to study therapeutic resistance in oncology. We have developed tools using these modalities to quantify facets of the tumor microenvironment. | A group with lymphatic biology expertise by which to apply our technology | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Donny Hanjaya-Putra | University of Notre Dame | dputra1@nd.edu | Notre Dame, IN | Our lab is working at the forefront of developing transdisciplinary approaches by combining stem cell and bioengineering, biomaterials and microfluidics, as well as lymphatic and systems biology techniques to develop the necessary component in therapeutic lymphangiogenesis. | We are looking for partners with clinically-relevant models for lymphedema to test and commercialize our biomaterials and cell-based therapeutics. | TA1: Restore Flow Through Physical Interventions |
| Anne Taylor | Childrens Hospital of Colorado | anne.taylor@childrenscolorado.org | Denver, CO | We are in the process of building our lymphatic intervention offerings for patients with lymphatic abnormalities following cardiac surgery. We are particularly focused on lymphatic leak in patients with single ventricle heart disease following Stage III palliation with the Fontan procedure. | We would be very interested in exploring new imaging modalities for quick, precise, and accurate diagnostics. While dynamic magnetic resonance lymphangiography has been the gold standard modality, it often requires prolonged anesthesia for congenital heart disease patients. This time under anesthesia is often not well tolerated by patients with single ventricle physiology and other comorbidities. New modalities that do not require anesthesia in our young patients would be impactful. | TA1: Restore Flow Through Physical Interventions |
| Ikbal Sencan-Egilmez | Washington University in St. Louis | ikbal@wustl.edu | St. Louis, MO | Our lab is is focused on elucidating the complex interplay between oxygenation, blood and lymphatic flow, microvascular structure, and metabolism in health and disease. We integrate state-of-the-art in vivo optical microscopy methods, molecular probes, and new experimental approaches for preclinical animal studies in brain and beyond (retina, gut etc.) | experts in lymphatic & glymphatic system disorders and treatments | TA1: Restore Flow Through Physical Interventions |
| Michael Harman | New England Medical Innovation Center | Michael.w.harman@gmail.com | Providence, RI | The New England Medical Innovation Center (NEMIC) is a 501(c)(3) nonprofit located in Rhode Island that provides expert education, connections to funding, and specialized expertise to innovators and entrepreneurs in the medical technologies space. As the region’s premier HealthTech venture hub, we deploy our unique gap analysis approach, draw on an extensive network of subject matter experts, and facilitate clinical access in order to bridge the valley and turn ideas into reality. | NEMIC is primarily seeking partners with biosafety laboratory capabilities to run studies. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Eric Song | Yale University, Rho Bio | eric.song@yale.edu | New Haven, CT | We engineered a potent lymphatic specific agonist that is completely decoupled from unwanted angiogenesis. We aim to bring this molecular therapy to clinic not only to help treat lymphatic based drugs, but also to show that the lymphatic system is an actionable target. | We are looking for partners that can 1.) Provide new delivery methods of our molecule and 2.) provide new models to help us get closer to IND enabling studies. We have strong preclinical data with a recombinant version of the protein that we optimized, but also understand the strengths of other delivery modalities such as mRNA and long lasting polymer/hydrogel formulations. If there are teams that have delivery expertise, we believe we would synergize greatly with them. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Katharina Maisel | University of Maryland | maiselka@umd.edu | College Park, MD | My lab’s research integrates nanotechnology, materials science, and tissue engineering with physiology, medicine, and immunology to probe and target lymphatics using nanoparticles. We have made significant progress in understanding how nanoparticle material properties like surface chemistry, affect their transport across biological barriers including lymphatic vessels. | My lab's research focuses on how to get drugs to the lymphatics, so we are looking to partner with those who have specific therapeutics in mind | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Babak Mehrara | Memorial Sloan Kettering Cancer Center (MSKCC) | katarur@mskcc.org | New York, NY | Our lab investigates breast cancer-related lymphedema, bridging basic science and clinical practice. We use patient samples & animal models to identify and target key inflammatory pathways to improve lymphatic function. We've successfully tested FDA-approved drugs in topical formulations, targeting these pathways in preclinical models. These promising results have paved the way for larger animal studies and eventual human trials, bringing us closer to effective BCRL treatments. | We seek collaborative partnerships for our TA2 application, specifically with academic and industry experts in pharmacology, toxicology studies, drug formulation, and large animal models. Additionally, we are interested in collaborating with TA1 partners specializing in physical and surgical interventions for lymphedema and lymphatic dysfunction, with the aim of submitting a joint application. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy, TA1: Restore Flow Through Physical Interventions |
| Hope O'Donnell | Spring Science | hope@springscience.com | San Carlos, CA | Spring provides advanced AI image analysis tools to researchers across a broad spectrum of applications, using cellular morphology and proteomics to solve complex mechanisms, screen compound libraries, assess clinical biomarkers, develop outcome predictive models, and more. Our expertise in high content imaging, including designing and running assays, ensures robust results across sample types. Custom, web-based AI analysis software simplifies data sharing for multi-institution collaborations. | We are looking for partners who are either interested in screening candidates for TA2 or have a subset of candidates that they would like to further characterize. We can screen or test candidates using AI analysis of cell morphology in cell lines, PBMC, or other primary cells in vitro, or work with other teams to analyze images and other data generated in more complex model systems. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Kazuhide Shaun Okuda | La Trobe University | k.okuda@latrobe.edu.au | Melbourne, Australia | My research program's focus is on identifying mechanisms and therapeutic leads to enhance lymphangiogenesis using the unique zebrafish model. I have access to and is establishing novel zebrafish lymphoedema models that can be used to test these hypothesis. | Researchers interested in utilising the zebrafish model (live-imaging, high throughput drug discovery, disease modelling) to accelerate in vivo discovery of lymphoedema therapeutics and targets. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Huiliang Wang | University of Texas at Austin | evanwang@utexas.edu | Austin, TX | Ultrasound-triggered drug release for targeted delivery, Gene (DNA and mRNA) delivery, Sono-optogenetics, ultrasound neuromodulation. Non-viral DNA/mRNA delivery. | Expertise in lymphatic & glymphatic system, lymphatic disease and interventions, lymphatic disease models, drugs for treating lymphatic disease and clinical doctor lymphatic disease | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy, TA1: Restore Flow Through Physical Interventions |
| Michelle Farrington | AFFOA | mfarrington@affoa.org | Cambridge, MA | National Manufacturing Institute with a focus on advanced textile technologies. Research area focus includes advanced sensing and actuation technology integrated into textile form factors. 3D and circular knitting, weaving and embroidery available at our facility along with electronics and soft system integration and product design. We also have 150 member network from the domestic supply chain ready to bring a domestic supply chain to those working to accelerate a product's time to market. | Clinical expertise in lymphatic disorders and compression based interventions. | TA1: Restore Flow Through Physical Interventions |
| Lydia Gushgari | SPOC Proteomics | lydiag@spoc.bio | Scottsdale, AZ | SPOC Proteomics developed a novel protein-biosensor platform for simultaneous kinetic (affinity) screening of 1000 proteins or antibody-based therapeutic candidates on a single chip, at 1/10th the cost compared to current recombinant protein workflows. SPOC biosensors support high-throughput pre-clinical drug discovery, wet lab testing of AI-designed drugs, affinity ranking, lead candidate selection, and data generation to train AI/ML models. SPOC protein biosensor chips are customizable. | SPOC Proteomics is interested in partnering with TA2 proposers to support high-throughput drug discovery through kinetic screening, generating data to train AI models, epitope mapping/binning, off-target screening, to enable down selection of antibody-based drugs/biologics, CARs, PROTACs, and/or small molecules. We are looking for partners with specific disease expertise, AI-enabled drug developers, with the expertise to conduct the preclinical and clinical studies required by the program. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Theodore Alexandrov | University of California San Diego | talexandrov@health.ucsd.edu | San Diego, CA | We have developed a method for single-cell metabolomics of lymphocytes. The method provides comprehensive metabolic profiles for single lymphocytes isolated from blood and reflects the metabolic and functional states of immune cells and their heterogeneity. It can be used to infer the metabolic mode of action of drugs or therapies as well as help understanding metabolic reprogramming of lymphocytes or CAR-T cells in diagnostics, therapy development and response monitoring. | We are looking for clinical partners to make translational impact with our technologies as well as for methodological collaborators to jointly develop better technologies for these aims, in particular in the single-cell analysis space | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Robin Smith | Wonderlab Bio | robin@wonderlab.bio | Boston, MA | Our organization has allogenic cell lines for use in cell therapies that match 90% of the US population. These lines are available for teaming or partnership for manufacturing and research and development. | We would like to team with organization to supply necessary allogeneic cell lines derived from iPS cells for the purposes of this program. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| David Nelles | Tacit Therapeutics, Inc. | dnelles@tacittx.com | San Francisco, CA | Tacit Therapeutics has created a RNA repair technology that supports the repair of multiple kilobases of specific RNAs. We propose improving lymphatic function by altering expression of specific genes using our proprietary RNA trans-splicing process to repair mutations and introducing beneficial variants | We are interested in teaming up with organizations that have validated gene delivery vectors that can target lymphatic tissues | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| ALEX RICHARDSON | Second Heart Assist | arichardson@secondheartinc.com | Irvine, CA | SHA has developed a platform of mechanical circulatory devices that improve flow which directly interacts w/ the lymphatic system that can mitigate lymphatic dysregulation. It dramatically enhances cardiac & renal function, resulting in significant increase in diuresis, thereby reducing edema in the peripheral tissues, in turn reduces interstitial tissue pressure which can significantly enhance lymphatic flow /drainage through improved renal perfusion and oncotic & hydrostatic pressure gradients | SHA would like to work with synergistic teams to improve lymphatic dysfunction and project goals | TA1: Restore Flow Through Physical Interventions |
| Corin Williams | The Charles Stark Draper Laboratory, Inc. | cwilliams@draper.com | Cambridge, MA | Draper is a not-for-profit engineering R&D company whose mission is to address challenges of national importance, including healthcare. Relevant to GLIDE, we are developing sutureless technologies for medical devices and surgical applications. | Clinical partners | TA1: Restore Flow Through Physical Interventions |
| Masaru Rao | University of California, Riverside | mprao@ucr.edu | Riverside, CA | We have developed nanofabrication technologies that enable, for the first time, realization of TITANIUM-based, multi-functional nanodevices. These Ti Nanofab technologies leverage existing semiconductor process infrastructure, thus ensuring scalability to low-cost/high-volume manufacturing, as well as opportunity for high-density multi-functional integration (e.g., mechanical, electrical, fluidic, etc.). They also leverage Ti's mechanical robustness and well-established biocompatibility. | We are interested in serving in a support role, where our unique Ti Nanofab capabilities enable realization of revolutionary multi-functional nanodevices for lymphatic vessel (LV) repair &/or regeneration. Potential examples include, but are not limited to: 1) Nanostents for restoring LV flow; 2) Nanosurgical tools; 3) Sutureless anastamosis nanodevices; 4) Nanoimplants for lymphatic system repair & modulation; 4) Nanoneedles for targeted drug delivery. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Atefeh Rabiee | University of the Pacific | arabiee@pacific.edu | Stockton, CA | Cell biology and physiology of Lipedema adipocytes, Lipedema is a chronic lymphatic disorder. The exessive fat in Lipedema is resistant to calory burning, and we are investigating the molecular mechanism underlying Lipedema fat resistance. We apply, molecular biology, cell biology, microscopy, and mass spectrometry. Our available resources are stem cells from Lipedema patients. We also perform in vitro drug screening on Lipedema cells. | We are looking for additional resources such as blood, lymph, etc. We are also looking for more pharmacological insights, potential animal models... | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Jessica McDonough | Attivare Therapeutics | j.mcdonough@attivaretx.com | Natick, MA | Attivare Therapeutics was established by a team from Harvard to develop novel biomaterial-based therapeutics. We are advancing development of the AttImmune platform, which can recruit in target immune cells and safely deliver immune agonist signals (cytokines/chemokines) locally to cells. Our initial target areas are cancer and vaccines, and we believe that our approach has broad applicability to lymphatic disorders. | We would like to partner with orgs that have expertise in cytokines modulating lymphatic disorders. We would also like to partner with orgs that have lymphatic diagnostic techniques for preclinical and clinical lymphatic disorders. | TA1: Restore Flow Through Physical Interventions |
| Boaz Eidelberg | Skeletal Axes Assistive Robots Inc. | beidelberg@saar-inc.com | Daytona Beach, FL | exoskeletons can relate to lymphatic interventions and drug exploration in several ways, especially when considering their applications in rehabilitation, medical research, and drug delivery systems | 1. **Data Collection**: Exoskeletons equipped with sensors can collect valuable data on joint movement, muscle activity, and lymphatic flow. This data can inform drug development by providing insights into how drugs affect the lymphatic and muscular systems. 2. **Real-time Monitoring**: Patients using exoskeletons can be monitored in real-time to assess the impact of drugs on mobility and lymphatic function. This could lead to more precise adjustments in drug dosages and treatment plans. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Sharron Lin | MGH | slinteam1@gmail.com | Boston, MA | Role of lymphatic system and improving the imaging tools for diagnose diseases related to/involved in the lymphatic system | Team interested in understanding the function of lymphatic system | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Kenneth Wang | AtlasXomics Inc. | kenw@atlasxomics.com | New Haven, CT | AtlasXomics Inc. provides a transformative spatial multi-omics platform. The Deterministic Barcoding in Tissue for spatial omics sequencing (DBiT-seq) platform combines microfluidics and next generation sequencing (NGS) to bring spatial context to standard bulk molecular assays. First to market (and still only) spatial assays for chromatin accessibility and histone modifications help cancer investigators analyze the tumor microenvironment. | AtlasXomics can provide insight into the tissues and cell populations that are impacted by teaming partners' therapies on treated versus control subjects. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Michael Paukshto | Fibralign Corp | mpaukshto@fibralignbio.com | Union City, CA | Fibralign’s novel devices direct and promote lymphatic vessel regeneration that has been demonstrated in multiple preclinical and clinical studies. First product, BioBridge®, has been used successfully in over 350 surgeries for treatment of lymphedema with no complications or adverse events related to the device. Next generation of BioBridge device will target neurological disorders where the impaired meningeal and/or deep cervical lymphatics reduce CSF drainage and diminish immune function. | Expert in anatomy of meningeal and cervical lymphatics; quantitative evaluation of CSF drainage to the cervical lymph nodes (human, animal model); contrast enhanced high frequency ultrasound for mapping deep cervical lymphatics (human, animal model). | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Melissa Aldrich | UTHealth | Melissa.B.Aldrich@uth.tmc.edu | Houston, TX | Lymphedema secondary to cancer treatment, lymphedema associated with Turner Syndrome. Understanding molecular and cellular mechanisms driving development and maintenance of secondary lymphedema | Vaccine development and production | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Amina Qutub | UTSA | amina.qutub@utsa.edu | San Antonio, TX | Our UTSA - UT Health team develops experimental-computational frameworks to rapidly screen therapies for rare and common diseases. This includes AI screens and metabolic imaging modalities to assess functional restoration in capillaries and lymphatics. | Lymphatic disease communities and patients, biotechs developing non-invasive imaging devices | TA1: Restore Flow Through Physical Interventions |
| charles kim | Mass General Hospital Cancer Center, NewCo | charleskimck@outlook.com | Boston, MA | Our objective is to deliver a functional cure for all cases of lymphoma - regardless of acquired somatic mutations or tissue of origin - by drugging mechanisms of cellular plasticity vital to malignant progression. To accomplish this, we will pioneer the development of first-in-class chemical 'magnets' capable of reprogramming the phenotype of cancerous lymphatic cells, transforming them into benign cell states that demonstrate pro-apoptotic, non-metastatic physiology. | We are looking for collaborative partners who are (1) building AI/machine learning algorithms that accelerate hit-to-lead optimization, characterize epigenetic cell states during drug treatment, identify relevant clinical biomarkers for each lymphoma subclass, (2) developing small molecule therapeutic delivery technologies targeting the lymphatic system and (3) developing imaging capabilities of the lymphatic system in preclinical disease models. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| nick hughes | Acrobat Genomics | nick.hughes@acrobatgenomics.com | SF Bay Area, CA | Development of next-generation gene editing tools using computationally-guided high-throughput screening | Clinical and translational expertise | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Susan Thomas | Georgia Institute of Technology | susan.thomas@gatech.edu | Atlanta, GA | therapeutic delivery to lymphatic system, lymphatic targeting drug delivery technology, lymphedema, immunotherapy, lymphatic function modulators, combination therapy, sustained release technologies | clinical partners, chemical biologists, medicinal chemists, interventional radiologists, lymphatic biologists, pharmaceutical scientists, industry partners | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Natalie Trevaskis | Monash University | natalie.trevaskis@monash.edu | Melbourne, HI | Our team has extensive expertise in therapeutic delivery to the lymphatic system, including administration of novel systems via various routes to target tissue-specific lymphatics | We would be interested to partner with other teams that have therapeutic molecules that can benefit from targeted delivery to the lymphatics | TA1: Restore Flow Through Physical Interventions |
| James Moore | Imperial College London | james.moore.jr@imperial.ac.uk | London, UM | Developing an implantable device to be deployed during cancer surgery to re-establish lymphatic vessels and prevent lymphedema. The device is capable of gradual release of lymphangiogenic factors. | Those developing lymphangiogenic biopharma products that could benefit from localized gradual release. | TA2: Normalize Function Through Targeted Pharmacologic & Cell Therapy |
| Greg King | Fibralign Corp | gking@fibralignbio.com | Union City, CA | Fibralign is a startup dedicated to the development of therapeutic devices for repairing and restoring lymphatic function based on a novel bioengineered nanofibrillar collagen scaffolding technology, which has been shown to promote and direct lymphangiogenesis. Research areas are focused on addressing lymphedema, neurological disorders and other lymphatic-related diseases, and advancing the development of an injectable scaffolding platform and combination devices for localized drug delivery. | Researchers, clinicians, and surgeons focused on addressing lymphatic disorders and developing innovative treatments. Neurologists, clinicians, surgeons, and researchers working on further understanding the role the lymphatic system has in neurological disorders, with translational focus on therapeutic treatments, diagnostic imaging, and biomarkers. Organizations working on pharmacologic, gene, and cell therapies for lymphatic repair, with interest in a novel localized delivery device. | TA2: Normalize Function Through Targeted Pharmacologic & Cell Therapy |
| Vrad Levering | Triple Ring Technologies | vlevering@tripleringtech.com | Newark, CA | Triple Ring Technologies is a leading partner in developing science-driven products across medtech, life sciences, and sustainability. Our interdisciplinary team, including many PhDs, excels in advancing technologies up the TRL scale and collaborating with academic researchers. We have a strong track record of engaging with ARPA-H, both as subcontractors and primary awardees. We offer services from basic tech development to prototype design and manufacturing. Fully ISO 13485 certified. | TRT partners with innovators to solve tough problems, launch breakthrough products, and create new businesses. From concept to FDA submission and commercialization, we handle technology development and redesign, and complex system integration. We welcome teaming partners with medical or specific domain expertise, and encourage bold ideas beyond current limits. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Benjamin Levi | University of Texas Southwestern | Benjamin.levi@UTSouthwestern.edu | Dallas, TX | Our research team has expertise and interest on the role of lymphatics on musculoskeletal injury, repair and regeneration. Specifically, we focus on understanding the role and interaction of lymphatics with local progenitor cells and myeloid cells to guide tissue repair, fibrosis and regeneration. We have expertise in models of muscle, tendon and bone injury and regeneration. Technically we have expertise in lineage tracing, single cell and spatial transcriptomics and metabolomics. | Our team is looking for partners in drug delivery platforms and imaging to assess lymphatic function. While we have shown lymphatic regeneration after musculoskeletal injury, having a partner with expertise on the function of these new lymphatics would help advance the science. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Joseph Wu | Stanford University School of Medicine | joewu@stanford.edu | Stanford, CA | drug discovery | synergistic partnership | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Brent Dixon | BioCytics | BDIXON@biocytics.com | Huntersville, NC | BioCytics, Inc., founded in 2005, has a focused mission to directly apply living cells in clinical trials as affordable individualized immune cellular therapies manufactured at the Point of Care (PoC). Expertise and services include clinical trials, research and development, GMP manufacturing, immunology, CLIA Lab assays, and biobanking/clinically annotated biospecimens. | Those looking for R&D laboratory services, proliferation assays, clinical development, prototype validation, GMP manufacturing of immune cells, and/or study design and clinical trials. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| June Wu | Columbia University | jw92@cumc.columbia.edu | New York, NY | We are broadly interested in basic and translational research in Vascular Anomalies. We have particular interest in slow-flow vascular malforations, including lymphatic malformations (LMs) and complex lymphatic anomalies (CLAs). We have focused on how genetic variants affect therapeutic response, as well as how genetic variants in LMs and CLAs affect biological behavior of diseased tissues. | We are looking for other Vascular Anomalies Centers as potential partners for multi-center clinical trials. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Mao Taketani | Quantum Sky | mao@jornatx.com | Cambridge, MA | RNA editing via trans-splicing technology | Scientists with expertise in lymphedema, or anyone with ideas on application of RNA editing technologies | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Esak Lee | Cornell University Biomedical Engineering | el767@cornell.edu | Ithaca, NY | Lymphatic tissue engineering and organ on a chip for building up initial and collecting lymphatic vessels with appropriate junctions and valves | Experts in animal models of lymphatic function and disease | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Andrzej Przekwas | CFD Research Corp | andrzej.przekwas@cfdrc.com | Huntsville, AL | Multiscale Quantitative Systems Pharmacology, linking systemic and lymphatic components. Developing novel formulation and delivery of therapeutics targeting lymphatic dysfunction. | Preclinical and clinical studies of therapeutics targeting lymphatic dysfunction. Providing QSP tools for translational studies and for personalized treatment protocols | TA1: Restore Flow Through Physical Interventions, TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Kazuhide Shaun Okuda | La Trobe University | k.okuda@latrobe.edu.au | Melbourne, Australia | My lab uses the zebrafish model to identify lymphatic regenerative mechanisms/leads to develop novel therapeutics for lymphoedema. To do this, we use zebrafish lymphoedema models, drug discovery and lymphatic vessel live-imaging. We take advantage of the optical transparency of zebrafish embryos/larvae to investigate how lymphatic regeneration occur. The high fecundity rate of zebrafish enables us to test multiple therapeutic leads, accelerating discovery of potential lymphoedema therapeutics. | I am looking for partners that are interested in using the zebrafish model to accelerate lymphoedema therapeutic development and to visualise/investigate mechanisms that drive this using zebrafish live-imaging. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| David Zawieja | Texas A&M University Health Science Center | dcz@tamu.edu | Bryan, TX | Development and regulation of lymph flow via phasic contractile activity of unique lymphatic muscle. Lymphatic muscle is a unique hybrid of striated and unstriated muscle phenotypes with the according contractile and regulatory elements.Isolated vessel techniques, high throughput small molecule library testing. | Drug delivery systems, lymphedema specialist physicians | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Kari Alitalo | University of Helsinki | kari.alitalo@helsinki.fi | Helsinki, Finland | Therapeutic lymphangiogenesis using VEGF-C gene/protein | Ability to support the clinical development of VEGF-C therapy beyond clinical phase 2 | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Louise Koelmeyer | ALERT Program, Macquarie University | louise.koelmeyer@mq.edu.au | Level 5, 75 Talavera Road, Macquarie University, NSW 2109, Australia | ALERT’s integrated, multidisciplinary approach focuses on translational clinical research for lymphatic diseases, particularly lymphedema. Using cutting-edge technologies like indocyanine green (ICG) lymphography, we improve assessment, management, and personalized treatment. Our research emphasizes early intervention, surgical advances, and better diagnosis of lymphedema and lipedema. The ALERT Databank supports research by providing patient data to inform best practices and enhance outcomes. | ALERT seeks partners in lymphedema, oncology, vascular diseases, and chronic care. We want collaborators with clinical expertise and access to advanced technologies like imaging and wearables. Ideal partners prioritize patient outcomes, global impact, and multidisciplinary collaboration. Key criteria include experience in bridging research and treatment, a focus on innovative therapies, and cross-disciplinary work. We welcome partners with access to target populations. | TA1: Restore Flow Through Physical Interventions |
| Mike Weiler | LymphaTech | mike@lymphatechnology.com | Atlanta, GA | LymphaTech focuses on developing advanced, non-invasive diagnostic tools for lymphatic health, improving the diagnosis and management of conditions like lymphedema. By leveraging cutting-edge imaging and data-driven technologies, LymphaTech provides accurate, real-time assessments of lymphatic function. Their innovations empower healthcare providers to deliver early detection, personalized care, and better outcomes for patients, enhancing the quality of lymphatic health management. | We are seeking teaming partners for a smart compression project targeting lymphedema management. Ideal partners should have expertise in wearable medical devices, sensor integration, and advanced textiles. We're looking for collaborators skilled in data analytics, pressure monitoring, and clinical lymphedema care, with experience navigating regulatory approvals. Partners should share our focus on innovation and improving patient outcomes through user-centered, effective solutions. | TA1: Restore Flow Through Physical Interventions |
| Mahzad Akbarpour | Rush University Medical Center, Chicago | mahzad_akbarpour@rush.edu | Chicago, IL | Stem/immune cell processing, process development and cGMP manufacturing ISO 8 and ISO 7 classified cleanrooms Point-of-Care cGMP manufacturing IND-enabling studies Cellular therapeutics quality control and release assays | Developing novel cellular therapeutics Technology transfer and process development | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Walter Cromer | TAMU | wcromer@tamu.edu | College Station, TX | The Lymphatic Biology Division at Texas A&M University is one of the premier lymphatic research organizations in the United States. We focus on muscle biology, inflammation, immunology and spaceflight in regards to lymphatic biology. | Those that have expertise in developmental biology and pharmacology. | TA1: Restore Flow Through Physical Interventions |
| Russell Ross | Sofusa | rross@vivasor.com | Atlanta, GA | Sofusa is a clinical stage biopharmaceutical company. Sofusa leverages its advantaged lymphatic drug targeting platform and proprietary knowledge of lymphatic drug targets and methods of treatment to develop a portfolio of next-generation treatments for autoimmune diseases and cancer. Our combination product development efforts are focused on transforming our science of the immune system and lymphatics into restoring healthy function to support the unmet medical needs in autoimmune and cancer. | Sofusa has primary focused on lymphatic targeting of pharmacological agents to restore health lymphatic function in autoimmune diseases and cancer. We are now looking to develop cell and gene therapy targets in the lymphatic system to treat a broader range of indications in autoimmune diseases and cancer. We will be looking for resources to help identify these targets and methods of treatment. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Reginald Swift | Rubix LS | rswift@rubixls.com | N/A, MA | Rubix LS focuses on accelerating breakthrough innovations to improve health equity, with key areas in early-stage clinical research, real-world evidence (RWE), and AI-driven platforms. We emphasize underserved populations, leveraging AI for patient recruitment, data management, and outcomes tracking. Our research spans diagnostics, digital therapeutics, and biotechnologies, aiming to transform health outcomes through innovative tools and methodologies. | Rubix LS seeks teaming partners who bring complementary expertise. We're targeting partners with strengths in AI, biotech, clinical methodologies, clinical research, real world evidence who are also focused on underserved communities. | TA1: Restore Flow Through Physical Interventions |
| Varun Singh | Massachusetts General Hospital | vsingh9@mgh.harvard.edu | Boston, MA | Our team works at the intersection of minimally invasive image-guided interventions and long-term delivery of cellular agents and therapeutics. We have developed a minimally invasive endovascular device suitable for deployment into the lymphatic, venous, orarterial system with immune-evasive characteristics for long term cellular, therapeutic, and drug delivery. Our use case has been endovascular islet cell transplantation for the treatment of Type 1 Diabetes Mellitus. | Biohybrid medical device engineering experts, materials science experts, pharmacologists, drug delivery experts, cell biologists, experts in therapeutics, and experts in therapeutic delivery | TA1: Restore Flow Through Physical Interventions |
| Eerik Kaseniit | Radar Therapeutics | eerik@radartx.bio | Berkeley, CA | Radar Therapeutics has created a technology for cell-type/cell-state specific control of protein expression for cell and gene therapies. The RADAR technology enables programmatically specifying which cells are able to express the therapeutic payload, enabling use of less-specific delivery vectors. This approach to targeting can enable addressing problematic cells, like cancerous cells, while leaving similar healthy cells untouched. | Validated delivery vectors for DNA or mRNA capable of lymphatic delivery (okay if non-specific within cell subpopulations, as our technology would address that). | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Stephen Hilbert | OncoSenX | stephen.hilbert@oncosenx.com | Seattle, WA | Oisn Biotechnolgies and OncoSenX use a novel delivery Proteo Lipid Vehicle (PLV) to deliver payloads such as DNA and RNA to cells. Our technology avoids an immune response by using a patented fusogenic protein to bind to cells. We have a tremendous amount of data showing efficacy in mice and non-human primates. We are currently developing drugs to tackle cancer, increase muscle mass and reduce inflammation. | We are looking for funding sources and partners to bring our pre-clinical assets to phase I trials. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Sanjay Misra | Mayo Clinic | glass.suzanne@mayo.edu | N/A, MN | Mechanisms responsible for hemodialysis graft failure as well as developing new therapies to improve patency of the hemodialysis vascular access that can be delivered using image guidance such as ultrasound, or stents and ballons coated with the therapy of interest. Additional working with the Center for Regenerative Biotherapeutics to bring cures to the practice through a unique ecosystem for the development, manufacture and delivery of novel regenerative biotherapeutics. | Partners with interests in translational medicine, pediatrics, microfluids, ultrasounds | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Michelle Lampa | Pasqal | michelle.lampa@pasqal.com | Boston, MA | We are a globally recognized neutral atom-based, analog quantum computing company creating enterprise-grade devices. As data sets become more complex, we strongly believe that quantum computing is needed to accelerate the groundbreaking work in the industries that affect our everyday lives, especially in the life sciences. | We are looking for entities who are working with complex data sets, e.g. drug discovery, optimization, among others. We can be the hardware provider and the partner that works with these potential teaming partners to identify the quantum algorithm that would provide the best outcomes. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Yonatan Lipsitz | Lilium Therapeutics | yonatan@liliumtx.com | Cambridge, MA | Targeted in vivo gene therapy and synthetic biology | Novel relevant targets and genetic payloads | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| nick hughes | Acrobat Genomics | nick.hughes@acrobatgenomics.com | San Carlos, CA | Acrobat Genomics has developed a novel high-throughput method that leverages advancements in computational methods, synthetic biology, and genomics in order to develop next-generation gene editing tools for therapeutic applications. | We are technology experts and are looking for partners that have expertise in lymphatics biology. We have preliminary therapeutic hypotheses that are well-suited to the unique features of our technology that we would like to refine with a partner. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Laura Powell | EverGlade Consulting | lpowell@everglade.com | Houston, TX | EverGlade Consulting helps companies secure and manage non-dilutive federal funding. We offer services ranging from proposal writing support through post-award program management and implementation of systems to comply with federal regulations. We have helped companies win ARPA-H awards through the successful preparation of solution summaries and full proposals. | EverGlade Consulting is available to assist partners in the preparation of solution summaries and full proposals to ARPA-H. We can also assist with negotiations and post-award contract administration, including program management support, preparation of contract deliverables, and invoicing. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Lee Jun Heon | KoreaCancerRehabilitationExerciseInstitute | zhzh0515@naver.com | Seoul | In the rehabilitation of lymphedema patients, we develop and study other forms of physical therapy approaches in addition to the existing MLD method or compression bandage, and educate Korean physical therapists about complex lymphatic physical therapy. | Study and research on various forms of surgical or physical interventions. | TA1: Restore Flow Through Physical Interventions |
| Shirali Nigam | Cogitamentum Bio | shirali@cogitamentumbio.com | Vienna, VA | At Cogitamentum Bio, we combine rigorous research expertise with strategic business acumen to drive the successful commercialization of biomedical technologies. Our services span in-depth market research, healthcare product management, business development, and AI-driven data solutions to accelerate product-market fit and adoption. We specialize in identifying high-impact applications, fostering strategic partnerships, and empowering biotech startups to scale and secure funding. | We’re eager to step in as Project Manager or Product Development Lead. We can also support the Inclusivity, Diversity, and Equity components as our team members bring extensive experience from prior roles in 'Access to and Quality of Care', having collaborated with state governments, insurances, patient groups, providers, CMS, and government officials. Their work on rollouts of COVID-testing and vaccines, equips Cogitamentum Bio to effectively address healthcare access challenges. | TA1: Restore Flow Through Physical Interventions, TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Michael Bennett | Calliope Biophysics | mbennett@calliopebiophysics.com | Orem, UT | We are proposing a scaffold-free tissue engineering approach using a ultrasonic "cuff". This cuff can be used to promote cell growth to assist in rebuilding damaged tissue, or alternatively used to clear blockages in the lymphatic system. We have demonstrated we can develop complex cell structures using this technique, and now aim to develop the device and deploy it in the clinical setting. Our team comprises experts in acoustics, engineering, and regulatory affairs. | We are looking to collaborate with physicians, clinical experts and patient advocates to assist in clinical trial design and clinical validation of our technology. | TA1: Restore Flow Through Physical Interventions |
| Huseyin Karagoz | Vanderbilt University Medical Center | huseyin.karagoz@vumc.org | Nashville, TN | Surgical treatment of lymphedema | Looking for collaboration with the teams that can provide better imaging to guide surgery | TA1: Restore Flow Through Physical Interventions |
| Hadi Nia | Boston University | htnia@bu.edu | Boston, MA | We develop novel technologies, such as crystal ribcage, to probe functioning lungs from whole organ down to cellular level in real-time. | We are able to test the effectiveness of therapies (compression-based or cell/molecular therapy) using our crystal ribcage model. Building synergy between different backgrounds and expertise. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Amanda Ellis | Grand Strand Clinical Trial Services | amandaellis@gsclinical.com | Myrtle Beach, SC | At GSCTS, we aim to bridge the gap between the drug development teams, investigative study sites in hospitals and clinics worldwide by providing medical writing/essential document development, clinical operations team training and oversight, and general scientific consulting. | We are looking to team with partners that need our services during drug development to bring their product to clinic. | TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |
| Kate Rowley | Lympha Motus Ltd | kateatwork@gmail.com | London UK | Breast cancer related lymphoedema prevention. | We are looking for partners for support enhanced efficacy or our implantable device or those developing methods to demonstrate the efficacy of the device | TA1: Restore Flow Through Physical Interventions, TA2: Normalize Function Through Targeted Pharmacologic, Gene, & Cell Therapy |